LYEL vs SLB · rev $6.0K vs P/E 12, rev $8.97B
Lyell Immunopharma Inc (LYEL) versus Schlumberger NV (SLB) — a side-by-side from cached financials, not a winner call.
Lyell Immunopharma Inc (LYEL) is a biotechnology company listed on US.
Schlumberger NV (SLB) is a oil & gas equipment & services company listed on US.
Latest reported LYEL revenue for 2026-06-30 was $6.0K. Net income was -$68.9M. LYEL currently screens at market cap $143.5M.
Latest reported SLB revenue for 2026-06-30 was $8.97B. Net income was $786.0M. Revenue was up 2.9% from 2026-03-31 to 2026-06-30. SLB currently screens at market cap $48.16B and trailing P/E 12.1.
LYEL currently screens at market cap $143.5M. SLB currently screens at market cap $48.16B and trailing P/E 12.1.
Not investment advice. Open the LYEL and SLB stock pages for the full models.
Not investment advice.